CCP has recovered Rs. 30 million from Reckitt Benckiser after a tribunal upheld findings that Strepsils ads misled consumers in Pakistan.
Key Takeaways:
- CCP recovered a Rs. 30 million penalty from Reckitt Benckiser Pakistan.
- The case centered on claims that Strepsils was presented like a medicinal sore-throat product.
- The tribunal upheld CCP’s finding under Section 10(2)(b) of the Competition Act, 2010.
- Strepsils is now registered as a food item, not a drug, making clear labeling essential.
- The ruling reinforces consumer protection and tougher action against misleading advertising.
Why the CCP Took Action Against Strepsils Ads
The Competition Commission of Pakistan has recovered a Rs. 30 million penalty from Reckitt Benckiser Pakistan Limited after a deceptive marketing case involving Strepsils reached an important legal conclusion. The recovery came after the Competition Appellate Tribunal upheld the regulator’s earlier findings and confirmed that the company had circulated misleading information about the nature and character of the product.
At the centre of the dispute was the way Strepsils was promoted to consumers in Pakistan. According to the regulator’s findings, the brand’s advertising created the impression that Strepsils remained a medicinal product for sore throat relief. The problem, however, was that the product had already been deregistered as a drug and was later being sold as a non-medicated product. In its current status, Strepsils is registered as a food item.
That distinction matters more than it may appear at first glance. Consumers often rely on packaging, advertising language, and visual presentation to decide whether a product is a medicine, a supplement, or a general consumable item. If a non-medicated product is marketed in a way that suggests therapeutic treatment, people may make buying decisions based on incomplete or incorrect information. For a watchdog like the CCP, that raises concerns not only about consumer rights but also about fair market competition.
The case shows that regulators are increasingly focusing on how products are positioned in the market rather than looking only at technical registration records. Even if a company does not directly use false wording in a narrow legal sense, the overall impression created by ads, packaging, and branding can still be judged misleading if it causes confusion about what the product really is.
How the Tribunal Upheld the Regulator’s Findings
The recent recovery follows an appeal against a CCP order issued on February 9, 2021. In that order, the Commission had concluded that Reckitt Benckiser violated Section 10(2)(b) of the Competition Act, 2010 by disseminating misleading information. The Tribunal has now upheld that conclusion, which gave the regulator the legal backing needed to recover the penalty.
The judgment is significant because it reinforces the idea that competition law is not limited to price fixing or monopoly abuse. It also covers the accuracy of claims made to the public. When a company markets a product in a way that can distort consumer understanding, that conduct can influence purchasing behaviour and create an unfair advantage over competitors that follow clearer and more transparent labeling rules.
The case originally began after a complaint from Square Distribution & Marketing System (Pvt.) Limited. The complainant argued that the company’s advertising and marketing campaigns were misleading consumers about Strepsils’ product status and characteristics. That complaint eventually led to the regulator’s inquiry, findings, and the appeal process that has now ended in favour of the Commission.
By upholding the CCP’s order, the Tribunal has also sent a message to large consumer brands that legal scrutiny does not end once a product has built recognition in the market. Well-known names are expected to meet the same transparency standards as everyone else. In practical terms, the ruling strengthens the CCP’s hand in future cases involving health claims, packaging impressions, and ambiguous brand messaging.
What Changes Reckitt Benckiser Must Now Implement
The Tribunal did not only uphold the penalty. It also directed the company to fully implement the corrective measures already prescribed by the Commission within the required timeframe. These steps are designed to reduce confusion and make the product’s true status clearer to consumers across Pakistan.
One major change noted in the proceedings was the company’s revised packaging and disclosure approach. Following CCP action, Reckitt Benckiser introduced more visible labeling on the front of the product packaging and on blister packs. The disclaimer “Non Medicated” was displayed prominently in both English and Urdu. This is an important corrective measure because it speaks directly to the concern raised in the case: whether consumers can easily understand what they are buying.
The company has also been directed to publicize the product’s changed status through advertisements in leading English and Urdu newspapers across the country until full compliance is achieved. This requirement goes beyond packaging alone. It means the company must actively inform the public that Strepsils is no longer in a medicated drug category and is being sold as a food product.
Such corrective advertising is important in markets where a product may have built long-term associations in the minds of consumers. People often continue to think of an old brand in the same way they did years earlier. A newspaper disclosure campaign can help bridge that gap by informing buyers who may not closely examine labels at the point of sale. It also shows that regulators want compliance to be visible, not just technical.
Why This Ruling Matters for Consumers and Businesses
For consumers, this case is a reminder that product labeling and advertising claims are not small technical matters. They shape public understanding and influence health-related buying choices. A person reaching for sore throat relief may assume a product provides medicinal treatment if the packaging and promotion strongly suggest that message. If that assumption is inaccurate, the consumer is not making a fully informed choice.
For businesses, the ruling is equally important. It shows that compliance is not only about registering a product under the correct category. It is also about ensuring that every public-facing message matches that category honestly and clearly. Companies selling consumer health, food, wellness, or hygiene products may now face greater pressure to review packaging language, visuals, disclaimers, and advertising themes to avoid similar disputes.
The CCP has said the recovery of the penalty reflects its ongoing effort to protect consumers and push businesses toward accurate and truthful disclosure. That broader policy direction matters because deceptive marketing can damage trust in the market as a whole. When consumers begin to doubt labels and advertising claims, responsible businesses also suffer because fair competition becomes harder to maintain.
In the bigger picture, the Strepsils case may become an important reference point in Pakistan for future disputes involving blurred lines between food, wellness, and medical-style branding. The message from the regulator is clear: if a product’s legal status changes, its market presentation must change just as clearly. Transparency is no longer optional branding hygiene. It is a compliance requirement with real financial consequences.
